A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.

Treatment of non-metastatic hormone-sensitive prostate cancer (nmHSPC) with enzalutamide (Xtandi) in combination with leuprolide acetate was associated with significantly improved overall survival (OS ...

Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

A recent study in JAMA Network Open found that although trimodal therapy (TMT) improved quality of life for patients with muscle-invasive bladder cancer, it was not as cost-effective as radical ...

Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Key Takeaways The PIVOT-PO trial was stopped early after meeting its primary end point of noninferiority to imipenem-cilastatin in treating cUTI. No new safety concerns were identified, with diarrhea ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4-5 in opposition of a favorable benefit-risk profile for UGN-102 (mitomycin) intravesical solution in adult patients with recurrent low-grade ...

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

This bill would cut funds for research projects in disease states such as prostate cancer, bladder cancer, kidney cancer, and interstitial cystitis.